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Abstract
Background: Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor
alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast cancer (BC).
The recent identification of ERα-36, a splice variant of ERα, has uncovered a new facet of this pathology. Although ERα-
36 expression is associated with poor prognosis, metastasis development, and resistance to treatment, its predictive
value has so far not been associated with a BC subtype and its mechanisms of action remain understudied.
Methods: To study ERα-36 expression in BC specimens, we performed immunochemical experiments. Next, the role of
ERα-36 in progesterone signaling was investigated by generating KO clones using the CRISPR/CAS9 technology. PR
signaling was also assessed by proximity ligation assay, Western blotting, RT-QPCR, and ChIP experiments. Finally,
proliferation assays were performed with the IncuCyte technology and migration experiments using scratch assays.
Results: Here, we demonstrate that ERα-36 expression at the plasma membrane is correlated with a reduced disease-
free survival in a cohort of 160 BC patients, particularly in PR-positive tumors, suggesting a crosstalk between ERα-36
and PR. Indeed, we show that ERα-36 interacts constitutively with PR in the nucleus of tumor cells. Moreover, it
regulates PR expression and phosphorylation on key residues, impacting the biological effects of progesterone.
Conclusions: ERα-36 is thus a regulator of PR signaling, interfering with its transcriptional activity and progesterone-
induced anti-proliferative effects as well as migratory capacity. Hence, ERα-36 may constitute a new prognostic marker
as well as a potential target in PR-positive BC.
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Background
Breast cancer (BC) is the most common cancer among
women worldwide. More than 75% of breast tumors express
the estrogen receptor α (ERα) in the nucleus and predomin-
antly belong to the luminal subtype. ERα plays a major role
in BC tumorigenesis as it regulates cell cycle, cell survival,
and angiogenesis [1]. Interfering with the ERα pathway
using anti-estrogens (either selective estrogen receptor mod-
ulators, such as tamoxifen, or selective estrogen downregula-
tors, such as fulvestrant) or through estrogen deprivation
(e.g., aromatase inhibitors) increases the survival of ERα-
positive BC patients. Despite the high level of sensitivity of
luminal tumors to endocrine therapy, treatment efficacy is
limited by intrinsic and acquired resistance [2, 3]. Indeed,
30–50% of patients relapse in the adjuvant setting and even-
tually die following the development of metastases [2, 4].
More recently, ERα-36, a splice variant of ERα, was identi-
fied as a novel actor of breast tumorigenesis. ERα-36 is
encoded by the ESR1 locus, transcribed from a promoter
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: muriel.leromancer@lyon.unicancer.fr
1Université de Lyon, F-69000 Lyon, France
2Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Centre Léon
Bérard, Bâtiment D, 28 rue Laennec, 69373 Lyon Cedex 08, F-69000 Lyon,
France
Full list of author information is available at the end of the article
Konan et al. Breast Cancer Research           (2020) 22:50 
https://doi.org/10.1186/s13058-020-01278-7
located in the first intron, resulting in a shortened receptor.
ERα-36 retains the DNA-binding domain, but lacks both
transactivation domains, AF-1 and AF-2. Furthermore, the
last 138 amino acids are replaced by a unique 27 amino acid
sequence at the C-terminal domain [5]. Compared to ERα,
ERα-36 displays distinct expression patterns. Indeed, while
ERα is mainly expressed in the nucleus of ERα-positive tu-
mors, ERα-36 is mainly expressed at the level of the plasma
membrane of breast tumor cells [6], co-localized with caveo-
lin, a typical cell surface protein [7, 8]. ERα-36 was shown to
activate ERK1/2 through the protein kinase C delta signaling
pathway, leading to an increase in the expression of cyclin
D1/CDK4, which increases cell cycle progression [9]. In
addition, binding of ERα-36 to ERK prevents its dephos-
phorylation by MKP3 and enhances a paxillin/cyclin D1
pathway [10]. Moreover, ERα-36 signaling contributes to the
potential invasion and metastatic spread of cancer cells by
upregulating aldehyde dehydrogenase 1A1 [11]. Surprisingly,
unlike ERα, ERα-36 is activated by the estrogen antagonist
tamoxifen and fulvestrant, both compounds routinely used
in ERα-positive BC treatment [8]. Accumulating experimen-
tal and clinical evidence supports that BC may arise from
mammary stem/progenitor cells which possess self-renewal
abilities. Recently, it was reported that ERα-36-mediated es-
trogen signaling plays an important role in the maintenance
of ERα-positive and ERα-negative breast cancer stem/pro-
genitor cells [12]. Moreover, overexpression of ERα-36 in
normal mammary epithelial cells causes loss of adhesion,
enhanced migration, and resistance to apoptosis [13].
ERα-36 is also a marker of poor prognosis in BC, and its
expression is associated with resistance to tamoxifen treat-
ment, probably due to its high expression in stem cells,
known to possess intrinsic resistance to treatment [11, 14].
The aim of this study was to investigate whether the
prognostic value of ERα-36 was associated with a par-
ticular subtype of BC. We unveiled a correlation be-
tween ERα-36 expression and poorer PR-positive patient
survival, suggesting a functional relationship between
ERα-36 and PR signaling. We clearly showed that ERα-
36 modulates PR expression and activity, regulating cell
proliferation, thus confirming its importance in BC.
Methods
Cell culture
T47D were cultured in RPMI-1640 medium, supplemented
with 10% fetal bovine serum (FBS), 2% penicillin-
streptomycin (Life Technologies), and insulin (10 μg/ml).
Cos7 cells were maintained in DMEM, supplemented with
10% FBS and 2% penicillin-streptomycin (Life Technolo-
gies). All cell lines were grown in a humidified atmosphere
with 5% CO2 at 37 °C, authenticated by Eurofins and tested
forMycoplasma infection (Lonza, Rockland, ME, USA).
Prior to experiments, when it was indicated, cells were
grown in phenol red-free medium supplemented with
10% charcoal-stripped serum (Biowest). Cells were then
treated with 10 nM of R5020 (Perkin Elmer) or E2
(Sigma) for the indicated times.
Generation of CRISPR ERα-36 KO cell lines
Electroporation of T47D cells
Cells were grown at subconfluence and electroporated
with CRISPR reagents after cell dissociation using the
Neon electroporator Invitrogen 1750 V-20ms-1pulse.
Electroporated cells were cultured as single cells to obtain
pure clonal populations.
Strategy
Guide RNAs were designed using an in-house genOway’s
tool, and those with the highest score were selected.
Targeted sequences were as follows: #1: 5′ TTAATA
AGTACACACCGCAG AGG 3′; #2: 5′ CTGTGAGGCC
TTATGACCAG AGG 3′.
These guide RNAs were designed to induce the deletion
of an ERα-36-specific sequence by cutting into intron 8
and downstream of exon 9 (intron 31 and exon 32 with
genOway’s numbering). ERα-36 isoform-specific knock-
out clones were amplified, and isolated DNA was charac-
terized by PCR amplification, as the 393-bp deleted se-
quence includes the ERα-36-specific exon 9 splice
acceptor site, coding sequence, and STOP codon.
Antibodies
Information of primary antibodies
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Technology
Rabbit 1/1000 1/500
Tubulin Sigma Mouse 1/10000
V5-tag (D3H8Q) Cell Signaling
Technology
Rabbit 1/1000












HeLa cells (7.5 × 104) were plated in 24-well plates 24 h
prior to transfection. The transfected DNA included
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100 ng of reporter plasmid and 25 ng of pRL-TK Renilla
luciferase vector (Promega) used as an internal control,
together with various amounts of expression vectors, as
indicated. Total transfected DNA was kept constant by
adding empty pSG5-Flag vectors. The cells were induced
with 10 nM R5020 24 h following transfection, then har-
vested after an additional 24 h and assayed for luciferase
activity following the manufacturer’s instructions. Lucif-
erase activities were normalized against the activity of
the internal control Renilla luciferase.
Immunofluorescence
T47D cells (2 × 105) were grown on coverslips in 12-well
plates. After treatment, cells were fixed in methanol for
2 min and washed twice in PBS. Non-specific binding
was blocked using a 1% gelatin solution for 30 min at
room temperature. Cells were incubated with PR anti-
body for 1 h at 37 °C, subsequently with the secondary
antibodies Alexa Fluor 488 anti-mouse (Jackson Immu-
noResearch, Cambridge, UK) (1:2000e) and Alexa Fluor
568 anti-rabbit (Invitrogen, Carlsbad, USA) (1:1000e) in
Dako diluent for 1 h. Finally, coverslips were mounted
on glass slides in mounting solution (Dako, Carpinteria,
CA, USA). The fluorescent slides were viewed under the
Nikon NIE microscope.
Immunoprecipitation and Western blot analysis
Cells were lyzed using RIPA buffer (50 mM Tris HCl,
pH 8, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and
0.25% deoxycholate) supplemented with protease inhibitor
tablets (Roche Molecular Biochemicals) and phosphatase
inhibitors (1mM NaF, 1mM Na3VO4, and 1mM β-
glycerophosphate). Protein extracts were incubated with
primary antibodies overnight at 4 °C on a shaker. Protein
G-Agarose beads were added, and the mixture was incu-
bated for 2 h at 4 °C. The immunoprecipitated proteins
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and analyzed by Western
blot, then visualized by electrochemiluminescence (ECL,
Roche Molecular Biochemicals).
Chromatin immunoprecipitation
ChIP experiments were performed according to the
manufacturer’s protocol (SingleChIP enzymatic chromatin
IP Kit - Cell signaling) with antibodies against PR, ERα,
and IgG. Results are expressed relative to the signal
obtained with chromatin input. Primer sequences are
indicated in the Additional file 1.
RNA extraction and real-time RT-qPCR analysis
Total RNA (1 μg) was extracted and purified using TRI
Reagent (Sigma-Aldrich, USA), prior to being reverse-
transcribed using 100 ng of random primers following
the Superscript II (Thermo Fisher, USA) protocol. Real-
time PCR was performed with SYBR Green qPCR mas-
ter mix (BioRad) in a Step One plus real-time PCR de-
tection system (Applied Biosystems). All amplifications
were performed in triplicate. Mean values of triplicate
measurements were calculated according to the −ΔΔCt
quantification method and were normalized against the
expression of 28S ribosomal mRNA as reference. Data
were presented as mean ± SEM. Sequences of the oligo-
nucleotides used are listed in Additional file 2.
Proximity ligation assay, image acquisition, and analysis
This technology exposes protein/protein interactions in
situ [15]. Briefly, cells were seeded and fixed with cold
methanol. After saturation, the different couples of
primary antibodies were incubated for 1 h at 37 °C. The
proximity ligation assay (PLA) probes consisting of
secondary antibodies conjugated with complementary
oligonucleotides were incubated for 1 h at 37 °C. The
amplification step followed the ligation of nucleotides
for 100 min at 37 °C. Samples were subsequently
analyzed under fluorescence microscopy.
The hybridized fluorescent slides were viewed under a
Nikon Eclipse Ni microscope. Images were acquired
under identical conditions at × 60 magnification. Image
acquisition was performed by imaging DAPI staining at
a fixed Z Position while a Z stack of ± 5 μm at 1 μm
intervals was carried out. The final image was stacked to
a single level before further quantification. On each
sample, at least one hundred cells were counted.
Analysis and quantification of these samples were
performed using the ImageJ software (free access). PLA
dots were quantified on 8-bit images using the “Analyse
Particles” command, while cells were counted using the
cell counter plugin.
IHC images were also acquired using a Nikon Eclipse
Ni microscope at × 40 magnification, and PLA dots were
quantified as described above.
Glutathione transferase pull-down assay
ERα-expressing plasmids were transcribed and
translated in vitro using T7-coupled reticulocyte lysate
in the presence of [35S] methionine. Glutathione trans-
ferase (GST) fusion proteins were incubated with labeled
proteins in 200 μl of binding buffer (Tris 20 mM pH 7.4,
NaCl 0.1M, EDTA 1mM, glycerol 10%, Igepal 0.25%
with 1 mM DTT and 1% milk) for 2 h at room
temperature. After washing, bound proteins were sepa-
rated by SDS-PAGE and visualized by autoradiography.
Proliferation studies
4 × 103 cells seeded onto a 96-well plate were plated 5 h
before incubation with the different hormones (E2,
R5020, or ethanol). Images were acquired using an Incu-
Cyte ZOOM over 7 days, and cell proliferation was
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measured as the percentage of cell density observed over
this period. Results are represented as graphs indicating
the rate of proliferation over time, extrapolated from at
least three independent experiments, each performed in
triplicate.
Wound healing assay
Cells were plated in duplicate in 6-well plates and grown
to confluence. Wounds were then performed with a
p200 pipette tip. After washes to remove cellular debris,
three images of each well were taken. The width of the
wound was measured at 3 places and recorded as t = 0.
The cells were then allowed to migrate back into the
wounded area. After 16 h, the width of the open area
was measured. Cell migration was expressed as the per-
centage of the gap (t = 16) relative to the primary width
of the open area (t = 0). Images were acquired on a phase
contrast microscope (Zeiss, Axiovert 25). All experi-
ments were performed in triplicate.
Patient population
We screened 200 consecutive female patients with
operable breast cancers who had undergone radical
surgery and received adjuvant/neoadjuvant therapy in
the Centre Léon Bérard between January 1999 and
December 2001. Paraffin blocks of tumor tissue were
available for 182 patients. Among these, we failed to
assess ERα-36 in 22 tumor specimens as a result of in-
sufficient tumor or tissue loss during TMA preparation.
Therefore, a total of 160 specimens were analyzed in this
study.
Patients underwent radical surgery (either modified
radical mastectomy (MRM) or breast-conserving surgery
(BCS) with axillary lymph node (LN) staging). ERα-66
and PR were detected by immunohistochemistry, and tu-
mors were considered positive if they display nuclear
staining in 10% or more of the tumor cells. HER2 ex-
pression was determined using immunohistochemistry,
and tumors were considered positive if they reached 3+
staining by immunohistochemistry or 2+ staining with
HER2 amplification detected by FISH.
The data exported from patient files for analysis
included age, histological subtype, maximum tumor size,
number of LNs involved, SBR grade, ER, PR, HER2
status, date of diagnosis, date of relapse, and date of
death or last clinical visit. Tumor samples and clinical
data were obtained with the approval of the Institutional
Review Board. This study is reported according to the
REMARK criteria [16].
Immunohistochemical analysis
The breast tumor samples were inserted as triplicates
using a 600-μm needle into 4 tissue microarray (TMA)
blocks. The blocks containing invasive carcinoma were
sectioned at a thickness of 4 μm. After deparaffinization
and rehydration, endogenous peroxidases were blocked
by incubating the slides in 5% hydrogen peroxide in ster-
ile water. For heat-induced antigen retrieval, tissue sec-
tions were boiled in 10 mM citrate buffer pH 6.0 (Dako,
Trappes, France) using a water bath at 98 °C for 50 min.
The slides were then incubated at room temperature
for 1 h with the antibodies against ERα-36 (rabbit poly-
clonal antibody). These antibodies were diluted using an
antibody diluent solution (Chemmate, Dako, Trappes,
France) at 1/50. After rinsing in PBS, the slides were in-
cubated with a biotinylated secondary antibody bound to
a streptavidin peroxidase conjugate (LSAB+ Kit, Dako,
Trappes, France). Bound antibodies were detected by
adding the substrate 3,3-diamino-benzidine. Sections
were counterstained with hematoxylin.
Blinded to the clinical data, biomarker expression was
evaluated by 2 observers who assessed both the
percentage and the intensity of the membranous
staining for ERα-36 in the infiltrative carcinomatous
cells only (faint cytoplasmic staining which was found in
almost all malignant cells was not considered).
For scoring purposes, the highest intensity of staining
in malignant cells was divided into 3 levels (0, no
staining; 1, weak staining; 2, moderate to strong
staining), and the percentage of stained cells was also
classified into 3 levels (0, no stained cells; 1, staining in
less than half of the malignant cells; 2, staining in half or
more of the malignant cells). Then, both intensity and
percentage scores were added to obtain a single score
(from 0 to 4) in a manner similar to the Allred score for
ER and PR staining [17]. For the purpose of correlation
and survival analyses, tumors were considered to have a
low expression for ERα-36 if they scored between 0 and
2 and were considered to have high expression above 2.
Statistical analysis
The correlation between ERα-36 expression and clinico-
pathologic characteristics was determined using Pear-
son’s chi-square test (or Fisher’s exact test). Distant
metastasis-free survival (DMFS) was defined as the time
from the date of histological diagnosis of breast cancer
to the date of distant metastasis or death. Disease-free
survival (DFS) was defined as the time from the date of
histological diagnosis of breast cancer to the date of any
cancer recurrence (local, distant, or contralateral) or
death. Overall survival (OS) was defined as the time
from the date of histological diagnosis of breast cancer
to the date of death. The database was locked at 12 years
of follow-up, and patients who were event-free at the last
follow-up visit (or at 12 years) were censored.
Survival curves, median DMFS, DFS, and OS (if
reached) in addition to 8-year DMFS, DFS, and OS (with
95%CIs) were derived from Kaplan-Meier estimates, and
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the curves were compared using log-rank test. Hazard
ratios and 95%CIs were calculated using Cox regression
model. Cox multivariate analysis was performed to de-
termine whether a factor is an independent predictor of
DMFS, DFS, or OS after adjusting for other significant
factors at the univariate level. All statistical tests were
two-sided, and the p value was considered statistically
significant if inferior to 5%. Statistical analyses were per-
formed using SPSS 20.0 statistics package.
Results
Clinico-pathological characteristics
We evaluated ERα-36 expression in a cohort of patients
displaying invasive breast cancer using our polyclonal
antibody specifically recognizing the ERα-36 isoform,
which has already been validated for IHC experiments
[10]. Table 1 summarizes the clinico-pathological char-
acteristics of the patient cohort tested. For the 160 as-
sessable patients, the median follow-up interval was 10
years (ranging from 0.2 to 12 years). Median age at diag-
nosis was 56.9 years (ranging from 30.4 to 87.4 years).
Regarding tumor stage, 57.5% of patients displayed tu-
mors exceeding 20 mm, and 52.5% had axillary lymph
node (LN) metastases. 16.3% of the patients had SBR
grade I tumors, 44.4% had grade II tumors, and 39.4%
grade III tumors. Adjuvant chemotherapy was adminis-
tered to 63.1% of patients, while 83.1% received adjuvant
hormonal therapy.
Pattern of ERα-36 expression
Regarding the immunohistochemical (IHC) analysis of
ERα-36, most of the tumors displayed a faint diffuse
cytoplasmic ERα-36 expression (Fig. 1a), which for the
purpose of statistical analysis was discarded. However,
only 65 tumors (40%) had a high membrane expression,
while 95 (60%) had a low or were devoid of membrane
expression (Fig. 1a). The correlation between ERα-36 ex-
pression and different clinico-pathological parameters
was then statistically investigated (Table 2). No signifi-
cant association was observed between high ERα-36 and
age, menopausal status, tumor size, ERα-66 status, PR
status, and axillary lymph node metastasis, except for
high SBR grade (grade III) (p = 0.04).
High ERα-36 expression predicts poorer outcome in BC
At 8 years, rates of distant metastasis-free survival
(DMFS), disease-free survival (DFS), and overall survival
(OS) were all poorer in patients with high compared to
low ERα-36 expression, with 59.0% versus 76.6% (DMFS:
HR = 2.02, 95%CI 1.2–3.4, p = 0.007), 54.7% versus 70.9%
(DFS: HR = 1.69, 95%CI 1.1–2.7, p = 0.029), and 68.6%
versus 79.6% (OS: HR = 1.82, 95%CI 1.02–3.2, p = 0.040),
respectively (Fig. 1b). In the multivariate analysis, when
adjusted to tumor size, LN metastasis, and SBR grade
(other significant prognostic factors in the univariate
model), high ERα-36 expression was still an independent
predictor of poorer DMFS (HR = 1.93, 95%CI 1.1–3.3,
p = 0.016) with a tendency towards poorer OS (HR =
1.65, 95%CI 0.9–3.0, p = 0.09). In addition to ERα-36,
large tumor size (HR = 1.84, 95%CI 1.04–3.28, p = 0.04)
and high SBR grade (HR = 2.04, 95%CI 1.2–3.5, p =
0.008) were also an independent predictor of poor
DMFS in the same multivariate model.
Interestingly, the impact of ERα-36 expression on dis-
tant metastasis-free relapse was limited to PR-positive
patients (Fig. 1c). Indeed, in the PR-positive patient co-
hort, the 8-year DMFS rate was 57.2% in patients with
high ERα-36 expression compared to 84.7% in patients
Table 1 Clinico-pathological characteristics, treatment received,
and ERα-36 expression in the patient cohort tested (160
patients)
Characteristic Number Percent
Age group (years) < 50 51 31.9
> 50 109 68.1
Menopausal status Pre 57 35.6
Post 103 74.4
Tumor size (cm) < 2 68 42.5
> 2 92 57.5
Axillary LN metastasis No 76 47.5
Yes 84 52.5
SBR grade I 26 16.3
II 71 44.4
III 63 39.4
ERα-66 status Negative 14 8.8
Positive 145 90.6
Missing 1
PR status Negative 40 25.3
Positive 118 74.7
Missing 2
HER2 status Negative 129 84.9
Overexpressed 23 15.1
Missing 8
Breast cancer subtype Luminal 142 91.6
Basal 10 6.5
HER2 driven 3 1.9
Missing 5
Adjuvant Hormonal treatment No 27 16.9
Yes 133 83.1
Adjuvant (or neoadj) chemotherapy No 59 36.9
Yes 101 63.1
ERα-36 Low 95 59.4
High 65 40.6
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Fig. 1 Expression of ERα-36 in breast tumors. a ERα-36 expression was analyzed by immunohistochemistry (IHC) on formalin-fixed human tumors.
Representative images of different IHC staining profiles are shown (A: low expression; B: high expression). b Kaplan-Meier estimates of disease-
metastases free survival (DMFS) (left), disease-free survival (DFS) (middle), and overall survival (OS) (right) in patients with low (blue) versus high
(green) membranous ERα-36 expression. c Kaplan-Meier estimates of DMFS in patients with low (blue) versus high (green) ERα-36 expression in 2
groups of patients according to PR expression
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with low ERα-36 expression (p < 0.001). On the contrary,
in the PR-negative cohort, the difference in this rate was
non-significant with values of 60.7% and 52.2% in high
versus low ERα-36 expression (p = 0.59), respectively.
Altogether, these results show that ERα-36 expression
at the plasma membrane is a poor prognostic marker
impacting survival of PR-positive BC patients.
ERα-36 is a new partner of PR
Based on the previous results, we hypothesized that ERα-
36 could be a bad prognostic marker in PR-positive BC
because it interferes with progesterone signaling. To
evaluate whether these proteins interacted directly, we ini-
tially conducted a GST pull-down experiment. We found
that radioactive PR specifically interacts with the full
length ERα-36 and its truncated form ERα-36ΔC (trun-
cated C-terminal part), but not with the GST (Fig. 2a). By
separating the PR protein into 5 fragments (PR1 to PR5),
we further identified PR3 and PR5 fragments, as the sites
of ERα-36/PR interaction (Fig. 2b). We also validated the
interaction by co-immunoprecipitation after transfection
of both proteins into Cos7 cells (Fig. 2c). In addition, we
investigated this interaction and its localization in T47D
cells that express both proteins, using proximity ligation
assay (PLA) and specific antibodies. The images obtained
revealed red dots in the nucleus of T47D cells, illustrating
the interaction of ERα-36 with PR independently of pro-
gesterone treatment (Fig. 2d–f). The downregulation of
PR silencing its expression was performed to validate the
specificity of the ERα-36/PR interaction.
In conclusion, this nuclear interaction suggests that
ERα-36 could regulate PR transcriptional activity.
ERα-36 regulates PR expression
To further investigate the role of ERα-36 in progester-
one signaling, we used the CRISPR/CAS9 technology to
specifically knock out the exon coding the isoform. Gen-
omic DNA sequencing of ERα-36 KO clones of T47D
cells revealed deletion at the targeted site. By RT-PCR,
we evaluated the mRNA expression of the different
clones and chose F4 for wild type (WT) and A6 and G3
for KO clones (Fig. 3a). Next, we assessed the PR expres-
sion by Western blot and observed a significant decrease
in KO cells compared to WT cells (Fig. 3b). This effect
Table 2 Correlation between ERα-36 expression and clinico-pathological features
Variable ERα-36 low, no. (%) ERα-36 high, no. (%) p value
Age (years) Mean (+ SD) 56.6 (+ 12.3) 57.9 (+ 12.9) 0,43†
Age groups < 50 years 32 (33.7%) 19 (29.2%) 0.5
> 50 years 63 (66.3%) 46 (70.8%)
Side Right 42 (44.2%) 30 (46.2%) 0.8
Left 53 (55.8%) 35 (53.8%)
T. size < 2 cm 41 (43.2%) 27 (41.5%) 0.83
> 2 cm 54 (56.8%) 38 (58.5%)
LN met Negative 45 (47.4%) 31 (47.4%) 0.9
Positive 50 (52.6%) 34 (52.3%)
SBR grade Gr 1 13 (13.7%) 13 (20%) 0.039††
Gr 2 50 (52.6%) 21 (32.3%)
Gr 3 32 (33.7%) 31 (47.7%)
ERα status Negative 9 (9.6%) 5 (7.7%) 0.7††
Positive 85 (90.4%) 60 (92.3%)
PR status Negative 23 (24.5%) 17 (26.6%) 0.7
Positive 71 (75.5%) 47 (73.4%)
ERα/PR detailed ERα+/PR+ 71 (75.5%) 47 (73.4%) 0.78††
ERα+/PR− 14 (14.9%) 12 (18.8%)
ERα−/PR+ 0 (0.0%) 0 (0.0%)
ERα−/PR− 9 (9.6%) 5 (7.8%)
Her 2 status Negative 78 (85.7%) 51 (83.6%) 0.7
Over-expressed 13 (14.3%) 10 (16.4%)
Tam tamoxifen, AI aromatase inhibitor, Anthra anthracycline
*Correlations tested using Pearson’s chi-square test (2 sided) unless otherwise specified
†Difference between means using the Student t test
††Fisher’s exact test
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Fig. 2 (See legend on next page.)
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was not due to a decrease in ERα expression, as evi-
denced by the Western blot (Fig. 3b). We also studied
PR localization, which revealed that although the stain-
ing decreased in KO compared to WT clones, it
remained within the nucleus (Fig. 3c). We then con-
firmed that this decrease in PR expression occurred in
KO cells at the mRNA level by RT-qPCR (Fig. 3d). We
hypothesized that this decrease could be due to a defect
of ERα binding to the PR promoter, but the low level of
ERα binding on the chromatin did not allow us to con-
clude (Additional file 3).
ERα-36 regulates PR signaling
Next, we investigated whether ERα-36 regulates proges-
terone signaling. First, we treated T47D cells with
R5020, the progesterone analog for different periods of
time and performed Western blot analyses to measure
the ERK activation and PR phosphorylation on its main
sites: S294 and S345. As shown in Fig. 4a, although pPR
S294 and S345 decreased in KO ERα-36 clones com-
pared to the WT, P-ERK remained activated. Quantifica-
tion of the pPR/PR ratio showed that ERα-36 KO
reduced the phosphorylation of PR. Treating T47D cells
with an ERK inhibitor showed that ERK activity was par-
tially implicated in the phosphorylation of PR (Add-
itional file 4). The decrease in pPR was confirmed by
PLA, showing that both pPR in the nucleus are lower in
KO clones compared to the WT T47D cells (Fig. 4b, c).
We also assessed whether ERα-36 regulates PR tran-
scriptional activity, by performing reporter luciferase as-
says. We found that ERα-36 stimulates PR activity in a
dose-dependent manner (Fig. 5a). Next, we verified the
expression of known PR target genes, which appeared to
be downregulated (Fig. 5b and Additional file 5), upregu-
lated (Fig. 5c), or unchanged (Fig. 5d) in ERα-36 KO
clones compared to the WT clone. To evaluate whether
these variations in gene expression were related to a
change in PR binding, we performed ChIP experiments
with PR antibody and found that PR binding to
chromatin was not significantly modified in KO ERα-36
versus WT clones for all genes targeted irrespective of
their level of expression (Fig. 5e–g).
In conclusion, ERα-36 regulates the PR transcriptional
activity independently of PR binding to chromatin.
ERα-36 regulates progesterone-mediated cell proliferation
and migration
The effects of ERα-36 on cell proliferation were next
assessed using the IncuCyte technology. We found that
ERα-36 has no major impact on the proliferation of
T47D cells (Additional file 6). Although numerous stud-
ies have shown that PR is an important actor of breast
tumorigenesis and progression [18–20], progesterone
can also inhibit FBS- and E2-induced cell proliferation
[21–23]; we wondered whether ERα-36 was involved in
this process. Of note, we found that the inhibitory effect
of R5020 on serum-induced proliferation was lost in
ERα-36 KO compared to WT clones (Fig. 6a). Interest-
ingly, ERα-36 was also involved in R5020 regulation of
E2-induced proliferation. Indeed, while R5020 inhibited
the effects of E2 on cell growth in WT cells, this effect
on cell proliferation was abolished in ERα-36 KO cells
(Fig. 6b). The mechanism seems to be independent of
ERα/PR interaction since ERα-36 KO does not impair
their interaction (Additional file 7). Next, we investigated
whether ERα-36 played a role in the effect observed for
progesterone on cell migration. We found that ERα-36
KO significantly impeded cell migration of T47D cells in
the presence of R5020 (Fig. 6c, d).
Altogether, these results clearly demonstrate that ERα-
36 is involved in PR expression, signaling, and transcrip-
tional activity, highlighting a new regulator of progester-
one signaling.
Figure 6e summarizes a model established according
to our findings presenting the mechanisms of action
of ERα-36 on progesterone signaling. Consistently,
this splice variant of ERα regulates PR phosphoryl-
ation by participating in the activation of an as yet
(See figure on previous page.)
Fig. 2 ERα-36 interacts with PR. a A radioactive GST pull-down assay was performed by incubating in vitro 35S-labeled PR (PR #) with GST, GST-
ERα-36, and GST-ERα-36ΔC. The corresponding Coomassie-stained gel is shown below. Arrows indicate the full-length fusion proteins. b PR was
divided into 5 fragments (PR1 to PR5). Radioactive ERα-36 (ERα-36 #) was incubated with the different domains of PR fused to GST, and the
bound proteins were visualized by autoradiography. The corresponding Coomassie-stained gel is shown below. “>” indicates the full-length
fusion proteins. c pSG5Flag-ERα-36 and pCDNA3V5-PR were overexpressed in Cos7 cells. Cell lysates were immunoprecipitated with the anti-Flag
antibody, and the presence of ERα-36 and PR was visualized by Western blot using the anti-Flag and anti-V5 antibodies, respectively. The lower
panel shows the expression of the different proteins in the input. d Proximity ligation assay (PLA) was used to detect the cellular co-localization
of endogenous ERα-36 and PR in T47D, grown on coverslips in 12-well plates. Cells were transfected with control siRNA (siCtl) or with siRNA
against PR (siPR) and treated for the indicated times with 10 nM of R5020. PLA for ERα-36/PR interaction was performed with anti-PR- and anti-
ERα-36-specific antibodies. The nuclei were counterstained with DAPI (blue) (Obj, × 60). The detected interactions are represented by red dots. e
Quantification of the number of signals per cell was performed using computer-assisted analysis, as reported in the “Methods” section. The
mean ± SD of one experiment representative of three experiments is shown. f The efficacy of PR siRNA treatment analyzed by Western blot
analysis is shown in the left-hand panel and quantified in the right-hand panel where the PR expression relative to tubulin was quantified using
ChemiDoc MP (Biorad)
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unidentified kinase, and is also involved in its tran-
scriptional activity, modulating the expression of
genes participating in progesterone-mediated cell pro-
liferation and migration.
Discussion
ERα-36, the well-characterized splice variant of ERα
plays an important role in breast tumorigenesis, and its
expression has been associated with poor patient sur-
vival, owing primarily to its involvement in tamoxifen re-
sistance and metastasis development [11]. However, its
prognostic value has as yet not been studied in different
BC subtypes. In this work, based on a cohort of breast
cancer patients, we analyzed the expression of ERα-36
alongside patient outcome and traditional prognostic
markers and reveal that its poor predictive value is sig-
nificantly associated with PR-positive tumors. Moreover,
we identify ERα-36 as an important actor of progester-
one signaling, modulating its expression, transcriptional
activity, and anti-proliferative and migratory function in
breast cancer cells.
We herein found that while ERα-36 is weakly
expressed in the cytoplasm of almost all tumors, its
membrane expression occurs only in 40% of breast tu-
mors independently of ERα and PR status. These results
corroborate previous studies on ERα-36 expression in
BC [11, 14]. In addition, its expression was associated
with a high SBR grade and a decrease in patient survival
Fig. 3 ERα-36 regulates PR expression. a ERα-36 and actin mRNA expression were analyzed by RT-PCR in T47D clones: F4 (WT) and A6 (KO-ER36)
and G3 (KO-ERα-36). b PR, ERα, and tubulin expression were assessed by Western blot in the three clones. Western blot quantification was
determined comparing PR to tubulin using ChemiDoc MP (Biorad) to measure the chemiluminescence from the immunoblots. The values
represent the mean ± SEM of three independent experiments. The p value was determined comparing each ERα-36 KO clones to the WT using
Student’s t test. *p < 0.05, **p < 0.01. c PR expression was studied by immunofluorescence in the 3 clones. The nuclei were counterstained with
DAPI (blue) (Obj, × 40). d Total RNA was prepared and cDNAs analyzed by RT-qPCR with specific primers for PR. The values were normalized
against 28S mRNA and represent the mean ± SEM of three experiments. The p value was determined comparing each ERα-36 KO clone to WT
cells using Student’s t test. **p < 0.01, **p < 0.001
Konan et al. Breast Cancer Research           (2020) 22:50 Page 10 of 16
Fig. 4 ERα-36 regulates PR signaling. a WT and KO ERα-36 cells were treated with R5020 for the indicated times; cell extracts were then loaded
onto a gel and assessed by Western blot for PR, pPR-S294 and S345, P-ERK, ERK, and tubulin expression. Quantification was performed in the
right-hand panels. b Phosphorylation of PR on S345 was also studied by PLA using a specific antibody and an antibody recognizing PR in the WT
and the KO ERα-36 G3 clones. Quantification of the results is shown in the right-hand panel. c The same experiment was performed as in b to
measure the PR phosphorylation on S294
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in terms of OS, DFS, and DMFS, supporting published
results showing that ERα-36 is associated with the devel-
opment of metastases [11]. Of interest, we determined
that its prognostic value is significant in PR-positive tu-
mors versus PR-negative tumors, suggesting that ERα-36
could interfere with PR signaling. This observation, des-
pite based on a retrospective analysis of a single cohort,
is a door opener to dissect the details of the interaction
between the 2 proteins. By several approaches, we clearly
demonstrated that ERα-36 binds to PR. Interestingly, its
C-terminal domain is not involved in this interaction, in-
dicating that it interacts with PR via a domain shared
with ERα. We also identified that the interaction be-
tween ERα-36/PR occurs via its binding to 2 domains of
PR, namely PR3 and PR5, containing the DBD and the
LBD, respectively. The binding sites are different from
those of ERα, as it binds to 2 sites within the PR se-
quence located within PR1 and PR2 domains [24]. This
may explain why ERα-36 KO does not impede ERα
binding to PR (Sup. Fig. 3).
Interestingly, although ERα-36 is mainly localized in
the cytoplasm and at the plasma membrane of cells, it
interacts with PR exclusively in the nucleus of cells, sug-
gesting that ERα-36 could regulate the transcriptional
activity of PR. Indeed, ERα-36 has already been shown
to regulate the transcription of ALDH1A1 by binding to
its promoter [11].
We also showed that ERα-36 regulates PR expression
at the level of the mRNA. The low level of ERα recruit-
ment on PR promotor in T47D cells did not allow to
conclude whether this effect is mediated through ERα.
As miRNAs have been shown to control PR expression
[25, 26], we can hypothesize that ERα-36 could regulate
miRNA expression to modulate PR level within the cells.
Interestingly, we found that phosphorylation of PR on
S294 and S345 strongly decreased in cells KO for ERα-
36, indicating that ERα-36 may regulate the expression
and/or activity of kinases. However, although ERK was
described to phosphorylate these 2 residues, the kinase
is not involved in our present study as p-ERK was not
modified in cells KO for ERα-36, although PR
phosphorylation strongly decreased, and the ERK inhibi-
tor did not change the phosphorylation status of PR
(Sup. Fig. 2).
Given the fact that ERα-36 binds PR in the nucleus
and that S294 and S345 are involved in the transcrip-
tional activity of PR [27–29], we also assessed whether
ERα-36 could regulate PR-mediated transcription. A lu-
ciferase assay confirmed that ERα-36 activates the tran-
scriptional activity of PR on an artificial promoter and is
involved in the expression of several PR target genes, in-
cluding DUSP1, RGS2, and PDK4 (downregulated);
SGK1 (upregulated); and FKBP5 (unchanged). However,
Chip experiments showed that PR binding remains con-
stant for the genes tested. As we found that ERα-36
binds to the E domain of PR, which contains binding
sites for coregulators, we can hypothesize that ERα-36
could modulate the binding of coregulators in a gene-
dependent manner.
We also assessed whether ERα-36 could play a role in
the effects of progesterone on cell proliferation. The role
of progesterone in breast tumorigenesis is complex as
there is a differential effect of PR in normal and malig-
nant breast tissue [30]. Although administration of PR
agonist MPA to mice promotes the formation of mam-
mary tumors initiated by DMBA [31], it exerts a biphasic
response in cell lines, such as a rapid proliferation burst
followed by a sustained growth arrest [32–34]. More re-
cently, several articles clearly showed that in addition to
proliferative action, under certain circumstances, proges-
terone has also an anti-proliferative action in cellulo and
in vivo [22, 34, 35]. Interestingly, although ERα-36 has
no striking effect on cell growth, we found that its deple-
tion abolished the inhibitory effect of progesterone on
FBS- and E2-dependent cell proliferation. As Carroll’s
team demonstrated that this effect involves PR/ERα
interaction [22], we investigated whether this interaction
is modified in cells knock-out for ERα-36, but no differ-
ence was observed, suggesting that other mechanisms of
regulation may be involved. Indeed, Sartorius’s team
found that the inhibitory effect of progesterone on cell
proliferation is largely due to a direct binding of PR to
(See figure on previous page.)
Fig. 5 ERα-36 regulates PR transcriptional activity. a HeLa cells were transiently transfected with MMTV-LUC reporter plasmid and expression
vectors encoding PR (10 ng) and ERα-36 (from 50 to 200 ng) using Lipofectamine 2000. Transfected cells were grown in a hormone-free medium
for 48 h in the presence or absence of 10 nM R5020, and extracts of the harvested cells were tested for luciferase activity using the Promega
luciferase assay kit. The results were normalized as indicated and presented as the mean ± SEM of at least three independent experiments. The p
value was determined using Student’s t test. *p < 0.05, ***p < 0.001. b–d Clones of T47D were treated, or not (Eth), 6 h with 10 nM of R5020. Total
RNA was prepared and cDNAs analyzed by RT-qPCR with specific primers for SGK1, STAT5A, FKBP5, PDK4, DUSP1, and RGS2. The values were
normalized against 28S mRNA and represent the mean ± SEM of three experiments. The p value was determined comparing each ERα-36 KO
clones to the corresponding condition in the WT using Student’s t test. **p < 0.01, ***p < 0.001. e–g T47D clones, grown in a charcoal-stripped
serum for 48 h and then treated with 10 nM R5020 for 1 h, were subjected to ChIP assay using an anti-PR antibody. The precipitated DNA
fragments were used for qPCR analysis using specific primers for the indicated promoters. The results are expressed relative to the signal
obtained from input chromatin. The mean ± SEM of at least three experiments is shown. The p value determined by comparing each ERα-36 KO
clone to the corresponding condition in WT cells using Student’s t test was not significant
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the RNA polymerase III, regulating tRNA transcription af-
fecting gene sets at the translational level [35]. More re-
cently, Vicent’s team showed that progesterone negatively
regulates cell proliferation via a functional crosstalk with
the transcription factor C/EBPα [34]. Interestingly, we
found that the progesterone-induced C/EBPα expression
was dependent on ERα-36. In addition, DUSP1 was re-
ported to mediate inhibitory effects of progesterone on
cell proliferation [21, 34], and our present work describes
that ERα-36 KO also inhibit progesterone-induced DUSP1
transcription, potentially explaining how progesterone
fails, at least in part, to inhibit FBS- and E2-dependent cell
proliferation in ERα-36 KO cells.
In conclusion, we demonstrate herein that ERα-36 is
involved in progesterone anti-proliferative and migratory
effects. This latter could explain why in our study ERα-
36 expression in PR-positive tumors is associated with a
reduced distant metastasis-free survival.
Altogether, our present data show that ERα-36 is a
new regulator of PR, concomitantly acting on its expres-
sion and its activity. Further studies are required to val-
idate its use as a new biomarker for a subset of PR-
positive tumors with poor prognosis.
Conclusions
In conclusion, we confirmed that ERα36 expression at
the plasma membrane is a marker of poor prognosis.
However, its correlation with patient survival is only
observed in PR-positive tumors.
We also found that ERα36 regulates the signaling and
transcriptional activity of progesterone in cellulo.
Moreover, ERα36 is required for allowing the anti-
proliferative effect of progesterone as well as its role in
cell migration. Further studies are required to decipher
whether other biological processes are altered.
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